Upfront Radiotherapy May Benefit Medulloblastoma Patients With Li-Fraumeni Syndrome
Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.
Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.
The overall response rate after 2 treatment cycles was 78%.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Adding ibrutinib to standard chemoimmunotherapy improved the median progression-free survival by 2.3 years.
Researchers found that socioeconomic status, insurance, race, and rurality were all associated with telemedicine use.
Most patients completed at-home chemotherapy infusions as planned, and no one stopped treatment because of adverse drug reactions.
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
The rate of on-treatment deaths was 17.1% in the venetoclax arm and 3.3% in the control arm.